Skip to main content

Zimmer Biomet income statement

  • ZBH · NYSE
  • Medical devices
  • Health Care Equipment
  • S&P 500
$103.21−1.29%Close 13 Nov 2026

Zimmer Biomet reported revenue of $8.23 billion for fiscal year 2025 (the twelve months to 31 Dec 2025), up 7.2% from fiscal 2024. Net income was $705 million and diluted earnings per share $3.55.

From Zimmer Biomet's annual and quarterly reports, each period checked against accounting identities; a figure that does not pass is left blank. Fiscal years follow the company's calendar, the latest ending 31 Dec 2025. TTM is the last four reported quarters added up.

Annual

Zimmer Biomet income statement, annual
USDFY 2007FY 2008FY 2009FY 2010FY 2011FY 2012FY 2013FY 2014FY 2015FY 2016FY 2017FY 2018FY 2019FY 2020FY 2021FY 2022FY 2023FY 2024FY 2025TTM
Revenue$3.90B$4.12B$4.10B$4.22B$4.45B$4.47B$4.62B$4.67B$6.00B$7.68B$7.80B$7.93B$7.98B$6.13B$6.83B$6.94B$7.39B$7.68B$8.23B$8.57B
Revenue growth—+5.7%−0.6%+3.0%+5.5%+0.4%+3.4%+1.1%+28.3%+28.1%+1.6%+1.7%+0.6%−23.2%+11.4%+1.6%+6.5%+3.8%+7.2%—
Net interest income—————————−$355.0M−$325.3M−$289.3M−$226.9M−$212.1M−$208.4M−$164.8M−$201.2M−$218.0M−$292.8M−$288.5M
Cost of revenue$875.9M$997.3M$990.7M$1.01B$1.12B$1.13B$1.27B$1.24B$1.80B$2.38B$2.13B$2.27B$2.25B$1.82B$1.96B$2.02B$2.08B$2.19B$2.49B$2.60B
Gross profit$3.02B$3.12B$3.10B$3.21B$3.33B$3.35B$3.34B$3.42B$4.20B$5.30B$5.67B$5.66B$5.73B$4.30B$4.87B$4.92B$5.31B$5.49B$5.74B$5.97B
Gross margin77.5%75.8%75.8%76.0%74.8%74.8%72.2%73.3%70.0%69.0%72.7%71.4%71.8%70.2%71.3%70.9%71.8%71.5%69.7%69.7%
Research and development———$218.5M$238.4M$225.6M——————————————
Selling, general and administrative$1.52B$1.70B$1.73B$1.76B$1.83B$1.81B$1.75B$1.75B$2.28B$2.94B$3.10B$3.38B$3.34B$2.71B$2.84B$2.76B$2.84B$2.93B$3.26B$3.48B
Operating expenses$1.89B$2.03B$2.09B$2.29B$2.31B$2.30B$3.55B$3.64B$5.53B———————————
Operating income$1.13B$1.09B$1.02B$916.7M$1.02B$1.05B$1.07B$1.04B$467.3M$821.1M$799.3M$33.80M$1.14B$83.10M$860.3M$696.3M$1.28B$1.29B$1.10B$1.16B
Operating margin28.9%26.4%24.9%21.7%23.0%23.4%23.1%22.2%7.8%10.7%10.2%0.4%14.3%1.4%12.6%10.0%17.3%16.7%13.3%13.6%
Interest expense——$22.40M$60.20M$55.30M$72.90M$70.10M$63.10M$286.6M$357.9M$327.5M—————————
Income before tax$1.13B$1.12B$998.2M$860.2M$978.9M$990.1M$1.01B$939.4M$153.2M$399.6M$464.6M−$271.1M$905.8M−$105.2M$499.0M$403.5M$1.07B$1.04B$830.8M$884.5M
Income tax expense$357.9M$272.3M$280.8M$263.3M$218.9M$237.2M$229.5M$220.2M$7.00M$95.00M−$1.35B$108.2M−$225.7M−$96.00M$53.50M$112.3M$42.20M$131.4M$125.7M$115.8M
Effective tax rate31.6%24.3%28.1%30.6%22.4%24.0%22.8%23.4%4.6%23.8%−290%−39.9%−24.9%91.3%10.7%27.8%4.0%12.7%15.1%13.1%
Net income$773.2M$848.6M$717.4M$596.9M$760.8M$755.0M$780.4M$720.3M$147.0M$305.9M$1.81B−$379.2M$1.13B−$138.9M$401.6M$231.4M$1.02B$903.8M$705.1M$767.3M
Net margin19.8%20.6%17.5%14.1%17.1%16.9%16.9%15.4%2.5%4.0%23.2%−4.8%14.2%−2.3%5.9%3.3%13.8%11.8%8.6%9.0%
EPS · diluted$3.26$3.72$3.32$2.97$4.03$4.29$4.54$4.20$0.77$1.51$8.90−$1.86$5.47−$0.67$1.91$1.10$4.88$4.43$3.55$3.95
Diluted weighted average shares238M228M216M201M189M176M172M172M190M202M204M204M207M207M210M210M210M204M199M194M
Basic weighted average shares236M227M215M200M188M175M170M169M187M200M202M204M205M207M209M210M209M203M198M194M
EBITDA$1.36B$1.37B$1.36B$1.26B$1.38B$1.41B$1.43B$1.41B$1.18B$1.86B$1.86B$1.07B$2.14B$981.5M$1.80B$1.62B$2.23B$2.28B$2.19B$2.27B
EBITDA margin34.8%33.1%33.1%29.8%31.1%31.5%30.9%30.2%19.7%24.2%23.9%13.5%26.9%16.0%26.3%23.4%30.2%29.7%26.6%26.5%
Depreciation & amortization$230.0M$275.1M$337.4M$340.2M$359.9M$363.1M$358.5M$375.8M$712.4M$1.04B$1.06B$1.04B$1.01B$898.4M$937.7M$926.4M$951.7M$996.3M$1.09B$1.11B
Stock-based compensation$70.10M$69.90M$75.30M$62.00M$60.50M$55.00M$48.50M$49.40M$46.40M$57.30M$53.70M$65.50M$84.30M$73.80M$76.00M$105.0M$99.80M$101.0M$90.20M$97.10M
Dividends per share————$0.18$0.54$0.80$0.88$0.88$0.96$0.96$0.96$0.96$0.96$0.96$0.96$0.96$0.96$0.96$0.96

Quarterly

Zimmer Biomet income statement, quarterly
USDQ4 FY2023Q1 FY2024Q2 FY2024Q3 FY2024Q4 FY2024Q1 FY2025Q2 FY2025Q3 FY2025Q4 FY2025Q1 FY2026Q2 FY2026Q3 FY2026
Revenue$1.94B$1.89B$1.94B$1.82B$2.02B$1.91B$2.08B$2.00B$2.24B$2.09B$2.18B$2.06B
Net interest income−$50.30M−$50.70M−$51.10M−$54.30M−$61.90M−$66.20M−$79.30M−$75.40M−$71.90M−$68.80M−$72.90M−$74.90M
Cost of revenue$538.8M$512.3M$553.6M$538.6M$586.7M$549.8M$592.2M$559.3M$792.4M$576.2M$635.5M$594.5M
Gross profit$1.40B$1.38B$1.39B$1.29B$1.44B$1.36B$1.49B$1.44B$1.45B$1.51B$1.54B$1.47B
Gross margin72.2%72.9%71.5%70.5%71.0%71.2%71.5%72.1%64.7%72.4%70.8%71.2%
Selling, general and administrative$722.3M$736.2M$737.1M$709.7M$746.9M$758.8M$814.8M$811.4M$872.3M$849.9M$899.3M$855.0M
Operating income$354.2M$265.9M$351.3M$279.5M$389.0M$292.3M$300.0M$351.3M$154.5M$373.2M$326.1M$307.6M
Operating margin18.3%14.1%18.1%15.3%19.2%15.3%14.4%17.6%6.9%17.9%15.0%14.9%
Income before tax$284.5M$215.1M$302.2M$230.3M$289.0M$229.0M$224.6M$279.2M$98.00M$301.3M$255.1M$230.1M
Income tax expense−$135.2M$42.30M$59.10M−$18.90M$48.90M$46.50M$71.20M$48.00M−$39.90M$63.00M$55.50M$37.20M
Effective tax rate−47.5%19.7%19.6%−8.2%16.9%20.3%31.7%17.2%−40.7%20.9%21.8%16.2%
Net income$419.2M$172.4M$242.8M$249.1M$239.5M$182.0M$152.8M$230.9M$139.3M$238.1M$198.3M$191.6M
Net margin21.6%9.1%12.5%13.7%11.8%9.5%7.4%11.5%6.2%11.4%9.1%9.3%
EPS · diluted$2.01$0.84$1.18$1.23$1.20$0.91$0.77$1.16$0.70$1.22$1.03$1.00
Diluted weighted average shares209M206M206M203M200M200M198M199M198M196M193M191M
Basic weighted average shares208M205M206M202M199M199M198M198M197M195M192M191M
EBITDA$595.4M$504.5M$594.5M$530.4M$652.6M$546.7M$571.8M$634.9M$438.5M$643.2M$596.9M$589.6M
EBITDA margin30.7%26.7%30.6%29.1%32.3%28.6%27.5%31.7%19.5%30.8%27.4%28.6%
Depreciation & amortization$241.2M$238.6M$243.2M$250.9M$263.6M$254.4M$271.8M$283.6M$284.0M$270.0M$270.8M$282.0M
Stock-based compensation$25.30M$29.00M$26.40M$24.50M$21.10M$19.60M$21.20M$25.30M$24.10M$24.20M$24.60M$24.20M
Dividends per share$0.24$0.24$0.24$0.24$0.24$0.24$0.24$0.24$0.24$0.24$0.24$0.24

The main figures as JSON and plain text. See data and methodology.

ZBH in the terminal

Every line back twenty years, charts of any figure, segments and KPIs by quarter, valuation and alerts.